Get the Weekly Intelligence Brief — top committee picks every Sunday.
SYK · NYSE · STOCK

Stryker (SYK) Stock Analysis

Healthcare Updated August 23, 2026
$329.31
52W $281.00 – $396.86
58/100
$126.30B
33.9
0.77
AI Committee Verdict
Buy
58/100
Conviction: Moderate · 60% agreement · 5 analysts
+13.6%
-4.3%
3.13:1
Moderate

Is SYK Bullish or Bearish?

Bullish. Innellis AI committee rates Stryker Corporation (SYK) Buy with a composite score of 58/100 , based on 5 analysts with 60% agreement. Last updated August 23, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +16.73 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -3.27 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

Positive signals support the current rating — eps growing 27.7% yoy. The committee sees sufficient evidence to maintain the constructive view.

Bull & Bear Case

Bull Case
  • ROE of 16.4% shows genuine earnings power backing the valuation — Value
  • EPS growing 27.7% YoY — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
  • P/E of 35.2 is moderate-to-rich — Value
  • Price-to-book of 6.0x prices in significant intangible value — Value
  • MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 23, 2026
Overall Committee Score
58/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 50%
of 192 Healthcare peers
Value Analyst neutral
48 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 16.4% shows genuine earnings power backing the valuation
− P/E of 35.2 is moderate-to-rich
Growth Analyst bullish
70 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 27.7% YoY
Technical Analyst neutral
48 / 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
60 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3069.37)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 58.3 to 58.3.

Comparing 2026-08-22 to 2026-08-23 (1 day apart).

Technical Analysis

RSI (14)
41.5
Neutral
MACD Histogram
-2.124
Bearish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Hh Hl
Support
$315.07
Resistance
$373.99
Bollinger %B
0.17
Inside Bands
Price vs Moving Averages
EMA 9
$334.72 Below
EMA 21
$334.64 Below
EMA 50
$329.43 Below
EMA 200
$338.41 Below

Fundamental Analysis

Valuation
51
Growth
57
Profitability
78
Financial Health
97
Cash Flow
70
Valuation
P/E Ratio 33.9×
P/B Ratio 5.27×
PEG Ratio 1.25
Dividend Yield 1.06%
52W High $396.86
52W Low $281.00
Quality & Growth
ROE 1447.8%
ROA 678.5%
Gross Margin 6516.6%
Operating Margin 2202.7%
Revenue Growth YoY
Debt / Equity 0.62
AI Fundamental Assessment
P/E ratio of 33.9 (rich relative to a 15-40x range); Price-to-book of 5.3x; PEG ratio of 1.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 14.5%; Return on assets of 6.8%; Net margin of 14.4%; Gross margin of 65.2%; Current ratio of 2.16 (healthy short-term liquidity); Debt-to-equity of 0.62; Free cash flow per share is positive (12.26); Most recent quarter beat estimates by 4.7%; EPS growth accelerating (-41.8% -> +41.9% QoQ); Analyst estimates falling over recent quarters
Get the Full SYK Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime